Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Structure Therapeutics (NASDAQ: GPCR) has announced ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity treatment. The drug, designed as an oral Dual Amylin and Calcitonin Receptor Agonist (DACRA), is expected to enter Phase 1 clinical trials by year-end 2025.
Preclinical studies showed ACCG-2671 demonstrates potent target engagement, robust weight loss, and favorable safety profile supporting once-daily dosing. The company positions it as the most advanced oral small molecule amylin-based drug candidate, complementing their GLP-1 oral molecule GSBR-1290, with both intended for use as monotherapies and in fixed-dose combinations.
The drug showed cagrilintide-like efficacy in preclinical data with an oral small molecule profile, targeting amylin, a hormone that regulates glycemia and energy balance.
Structure Therapeutics (NASDAQ: GPCR) ha annunciato ACCG-2671 come il suo principale agonista della amiloide orale a piccole molecole per il trattamento dell'obesità. Il farmaco, progettato come un Agonista Duale del Recettore dell'Amiloide e della Calcitonina (DACRA), dovrebbe entrare nella fase 1 degli studi clinici entro la fine del 2025.
Gli studi preclinici hanno dimostrato che ACCG-2671 mostra un forte impegno verso il target, una robusta perdita di peso e un profilo di sicurezza favorevole che supporta una somministrazione una volta al giorno. L'azienda lo posiziona come il candidato farmaco a piccole molecole amiloidi orale più avanzato, in complemento alla loro molecola orale GLP-1 GSBR-1290, con entrambi destinati all'uso come monoterapie e in combinazioni a dosi fisse.
Il farmaco ha mostrato un'efficacia simile alla cagrilintide nei dati preclinici con un profilo di piccole molecole orali, mirando all'amiloide, un ormone che regola la glicemia e l'equilibrio energetico.
Structure Therapeutics (NASDAQ: GPCR) ha anunciado ACCG-2671 como su principal agonista oral de pequeñas moléculas del receptor de amiloide para el tratamiento de la obesidad. El medicamento, diseñado como un Agonista Doble del Receptor de Amiloide y Calcitonina (DACRA), se espera que entre en ensayos clínicos de Fase 1 a finales de 2025.
Los estudios preclínicos mostraron que ACCG-2671 demuestra un potente compromiso con el objetivo, una robusta pérdida de peso y un perfil de seguridad favorable que apoya la dosificación una vez al día. La compañía lo posiciona como el candidato a medicamento oral a pequeñas moléculas basado en amiloide más avanzado, complementando su molécula oral GLP-1 GSBR-1290, que se pretende utilizar tanto como monoterapias como en combinaciones a dosis fijas.
El medicamento mostró una eficacia similar a la de cagrilintida en datos preclínicos con un perfil de pequeñas moléculas orales, dirigido a la amiloide, una hormona que regula la glicemia y el equilibrio energético.
Structure Therapeutics (NASDAQ: GPCR)는 비만 치료를 위한 주된 경구용 소분자 아밀린 수용체 작용제로 ACCG-2671을 발표했습니다. 이 약물은 이중 아밀린 및 칼시토닌 수용체 작용제(DACRA)로 설계되었으며, 2025년 말까지 1상 임상 시험에 들어갈 것으로 예상됩니다.
전임상 연구에서 ACCG-2671은 강력한 표적 결합, 뚜렷한 체중 감소 및 하루 한 번 복용에 적합한 안전성을 보여주었습니다. 회사는 이 약물을 아밀린 기반의 가장 진보된 경구용 소분자 약물 후보로 포지셔닝하며, GLP-1 경구용 분자 GSBR-1290과 상호 보완적으로 작용할 것입니다. 두 약물 모두 단일 요법 및 고정 용량 조합으로 사용될 예정입니다.
이 약물은 아밀린을 표적으로 하여 혈당 및 에너지 균형을 조절하는 호르몬에 대한 경구용 소분자 프로필을 가진 전임상 데이터에서 cagrilintide와 유사한 효능을 보였습니다.
Structure Therapeutics (NASDAQ: GPCR) a annoncé ACCG-2671 comme son principal agoniste oral de petites molécules des récepteurs d'amylin pour le traitement de l'obésité. Ce médicament, conçu comme un Agoniste Double des Récepteurs d'Amylin et de Calcitonine (DACRA), devrait entrer dans les essais cliniques de Phase 1 d'ici la fin de l'année 2025.
Les études précliniques ont montré qu'ACCG-2671 fait preuve d'un fort engagement envers la cible, d'une perte de poids significative et d'un profil de sécurité favorable soutenant un dosage quotidien. L'entreprise le positionne comme le candidat médicament oral à petites molécules basé sur l'amylin le plus avancé, en complément de sa molécule orale GLP-1 GSBR-1290, les deux devant être utilisés en tant que monothérapies et dans des combinaisons à dose fixe.
Le médicament a montré une efficacité similaire à celle de la cagrilintide dans les données précliniques avec un profil de petites molécules orales, ciblant l'amylin, une hormone qui régule la glycémie et l'équilibre énergétique.
Structure Therapeutics (NASDAQ: GPCR) hat ACCG-2671 als seinen Haupt-oral kleinen Molekül Amylin-Rezeptor-Agonisten zur Behandlung von Fettleibigkeit angekündigt. Das Medikament, das als Duale Amylin- und Calcitonin-Rezeptor-Agonist (DACRA) konzipiert wurde, soll bis Ende 2025 in die klinische Phase 1 einsteigen.
Präklinische Studien zeigten, dass ACCG-2671 eine starke Zielbindung, signifikante Gewichtsreduktion und ein günstiges Sicherheitsprofil aufweist, das eine einmal tägliche Dosierung unterstützt. Das Unternehmen positioniert es als den am weitesten fortgeschrittenen oralen kleinen Molekül Amylin-basierten Medikamentenkandidaten und ergänzt damit ihr GLP-1 orales Molekül GSBR-1290, das beide sowohl als Monotherapien als auch in Fixkombinationen verwendet werden sollen.
Das Medikament zeigte in den präklinischen Daten eine Wirksamkeit ähnlich wie cagrilintide mit einem oralen kleinen Molekülprofil, das auf Amylin abzielt, ein Hormon, das die Glyämie und den Energiehaushalt reguliert.
- Lead candidate ACCG-2671 demonstrated robust weight loss efficacy in preclinical studies
- Favorable safety profile and pharmacokinetics supporting once-daily oral dosing
- Potential for fixed-dose combinations with their GLP-1 candidate GSBR-1290
- First-mover advantage as the most advanced oral small molecule amylin-based drug candidate
- Phase 1 trials not starting until year-end 2025
- Still in preclinical stage with no human trial data available
Insights
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans
ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025
Company to host conference call today at 4:30 p.m. Eastern Time
SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amylin is a hormone that plays an important role in regulating glycemia and energy balance and is recognized as a promising therapeutic target for obesity and related diseases due to its effects on reducing food intake and slowing the rate of gastric emptying. ACCG-2671 was designed as an oral small molecule Dual Amylin and Calcitonin Receptor Agonist (DACRA) and is expected to enter Phase 1 clinical development by year end 2025.
“We believe amylin-based therapies are an important next-generation component of the treatment landscape for obesity and related conditions due to their potential for significant weight loss, favorable tolerability profile, and lean muscle mass preservation,” said Raymond Stevens, Ph.D., Founder and Chief Executive Officer of Structure Therapeutics. “As an oral small molecule, we envision ACCG-2671 as an additional backbone therapy to improve scalability, combinability and ultimately expand patient access to amylin-based weight loss medicines. We are in a unique position to have a potentially best in class GLP-1 oral small molecule with GSBR-1290 and now the most advanced amylin oral small molecule, both intended for use as monotherapies and as backbones for fixed dose oral combinations.”
In preclinical studies, ACCG-2671 demonstrated potent and balanced in vitro activities toward the key amylin receptor and the calcitonin receptor. ACCG-2671 also further demonstrated robust in vivo efficacy and a pharmacokinetic (PK) and safety profile supporting once-daily oral dosing in humans.
“The preclinical data demonstrate cagrilintide-like efficacy with an oral small molecule profile, underscoring ACCG-2671’s potential as a meaningfully differentiated oral treatment for obesity and related conditions,” said Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics. “Our proven GPCR structure-based drug discovery platform enabled us to rapidly advance ACCG-2671 as the lead amylin receptor agonist. We are now developing a series of amylin-based drug candidates using our technology platform to maintain our leadership in this exciting space.”
Conference Call and Webcast Information
Structure Therapeutics will host a conference call and webcast today, December 17, 2024 at 4:30 p.m. Eastern Time. A live webcast of the call will be available on the Investor Relations page of Structure Therapeutics’ website at https://ir.structuretx.com/events-presentations/events. To access the call by phone, participants can use the dial-in numbers listed below:
US-based Investors: 1-844-826-3033
International Investors: 1-412-317-5185
Conference Call ID: 10195088
The webcast will be made available for replay on Structure Therapeutics’ website beginning approximately two hours after the live event. The replay of the webcast will be available for 90 days.
About Amylin, Amylin-based receptor agonists, and ACCG-2671
Amylin is co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. Amylin has important physiological effects including reducing appetite, increasing satiety, leptin sensitivity and energy expenditure. Preclinical data from current amylin-based treatments in development suggest a potential for amylin to reduce fat mass and preserve lean mass.
Two types of amylin-based treatments for the treatment of obesity are currently being developed: dual amylin and calcitonin receptor agonists (DACRAs) that target both the amylin and calcitonin receptors; and selective amylin receptor agonists (SARAs) that preferentially target the amylin receptor.
Structure Therapeutics is developing a series of both DACRAs and SARAs, as both approaches have demonstrated potential as obesity and chronic weight management treatment. Structure’s lead amylin-based molecule, ACCG-2671, is a DACRA that is being evaluated for use either alone or in combination with GLP-1R agonists to treat obesity and associated diseases. ACCG-2671 is the first disclosed oral small molecule amylin-based development candidate, with Phase 1 study initiation expected by year end 2025.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; any expectations regarding the safety, efficacy, tolerability, scalability or combinability of ACCG-2671, GSBR-1290 and other candidates under development; the ability of ACCG-2671 and GSBR-1290 to treat T2DM, obesity or related indications; the planned initiation of ACCG-2671’s Phase 1 clinical study; the potential for ACCG-2671 and GSBR-1290 to be the most advanced and/or a best-in-class oral small molecule; and the ability of the Company to expand patient access to amylin-based weight loss medicines;. In addition, when or if used in this press release, the words and phrases “expect,” “on track,” “plan,” “potential,” “promising,” “to be,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to the preliminary nature of the results due to length of the study and sample size and results from earlier clinical studies not necessarily being predictive of future results, potential delays in the commencement, enrollment and completion of the Company’s planned and current clinical studies, the Company’s ability to advance GSBR-1290, LTSE-2578, ANPA-0073, ACCG-2671 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the Company’s therapeutic candidates, competitive products or approaches limiting the commercial value of the Company’s product candidates, the timing and results of preclinical and clinical studies, the Company’s ability to fund development activities and achieve development goals, the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control, the impact of any global pandemics, inflation, supply chain issues, rising interest rates, future bank failures and other macroeconomic factors on the Company’s business, its ability to protect its intellectual property and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 8, 2024, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 13, 2024, and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ
When will Structure Therapeutics (GPCR) begin Phase 1 trials for ACCG-2671?
What are the key preclinical results for Structure Therapeutics' (GPCR) ACCG-2671?
How does Structure Therapeutics' (GPCR) ACCG-2671 work for obesity treatment?
What makes Structure Therapeutics' (GPCR) ACCG-2671 unique in the obesity treatment market?
